BDSI BioDelivery Sciences International Inc.

BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its plans to report its second-quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019. The company will host a conference call and webcast at 4:30 PM EDT to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date: Thursday, August 8, 2019
  
Time:4:30 PM EDT
  
Domestic:800-347-6311
  
International:720-543-0197
  
Passcode:868 4665
  
Webcast:

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. For more information, please visit us or follow us on or Twitter .

© 2019 BioDelivery Sciences International, Inc. All rights reserved.

Contact

Mary Coleman

Vice President, Investor Relations and Corporate Communications

BioDelivery Sciences International, Inc.

919-582-9050

EN
30/07/2019

Underlying

Reports on BioDelivery Sciences International Inc.

 PRESS RELEASE

BioDelivery Sciences International Announces ELYXYB™ is Now Available ...

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availa...

 PRESS RELEASE

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40 Transaction expected to close late in the first quarter of 2022 RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic...

 PRESS RELEASE

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year...

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of

BIODELIVERY SCIENCES sees an upgrade to Slightly Positive due to a bet...

The general evaluation of BIODELIVERY SCIENCES (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 21, 2021, the closing pric...

 PRESS RELEASE

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining ...

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032 RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. District Court of Delaware has issued an opinion in favor of BDSI in the company’s patent litigation against Alvogen Group, Inc. and its affiliates, who filed an Abbreviated New Drug Application (ANDA) for BDSI’s BELBUCA® prod...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch